HanAll BioPharma’s Collaboration Agreement with Harbour BioMed

Cooley advised HanAll on the transaction

HanAll BioPharma and Harbour BioMed signed a collaboration and license agreement to develop, manufacture and commercialize HanAll’s two novel biologics in Greater China, including Hong Kong, Macau and Taiwan. Cooley partner Kay Chandler (Picture) and special counsel Rena Kaminsky advised HanAll on the transaction.

The biologics to be developed are HL161, an antibody for the treatment of autoimmune diseases, and HL036, a solution for dry eye and other inflammatory diseases.

Under the terms of the agreement, Harbour will pay HanAll up to $81 million in upfront, development, registration and milestones payments in addition to royalties on net sales. HanAll reserves the rights to develop outside of Greater China.

Involved fees earner: Kay Chandler – Cooley LLP; Rena Kaminsky – Cooley LLP;

Law Firms: Cooley LLP;

Clients: Hanall Biopharma Co., Ltd.;


Author: Ambrogio Visconti